Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality. This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity. - Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients - Written by world-leading experts in the field of cardiotoxicity - Includes high-quality images, case studies, and test questions - Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment

Cardiotoxicity may be caused by radiotherapy and/or anticancer agents for many malignancies, adverse effects of some drugs in the context of medical intervention or heavy metal intake, especially during the anticancer therapy. This book intends to bring forward the recent development in toxicities from cancer treatment. It updates the possible mechanisms of cardiotoxicities of some anticancer agents and the suggested prevention and treatment strategies. This book contains many valuable contributions from the researchers in oncology and cardiology as well as the clinicians who are experts in this field.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease.

This latest book in the Clinical Cases in Cardiology series presents a variety of commonly and rarely encountered cases associated with ​cardio-oncology. It explores the history of the discipline and each case described features concise practically orientated information on how to appropriately carry out physical examinations and utilize diagnostic tests including electrocardiography and monoclonal antibodies. Practically focused guidance is also provided on how to apply therapeutic techniques and the latest management strategies appropriately. Clinical Cases in Cardio-Oncology provides a concise practically applicable guide of how to diagnose and treat a range of conditions associated with ​cardio-oncology, making it a critical addition to the literature on the topic and a valuable resource for all medical practitioners who encounter these patients in their day-to-day practice.

The possibility of getting a cardiovascular disease or cancer increases with advancing age. At the same time, relevant improvements in cancer therapy have resulted in the improvement of quality of life and the increasement of the survival rate of such patients. As a result we have larger number of patients that experience the cardiac side effects of chemotherapy. The extent of cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, prior mediastinal radiotherapy and the presence of cardiovascular risk factors or history of heart disease. Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.